These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23620452)

  • 41. [Role of high-dose chemotherapy and autologous blood stem cell transplantation in patients with diffuse large B-cell lymphoma].
    Gavrilina OA; Gabeeva NG; Morozova AK; Sidorova AA; Zvonkov EE
    Ter Arkh; 2013; 85(7):90-7. PubMed ID: 24137955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Rituximab with chemotherapy improves survival of non-germinal center type untreated diffuse large B-cell lymphoma.
    Saito B; Shiozawa E; Usui T; Nakashima H; Maeda T; Hattori N; Shimozuma J; Adachi D; Yamochi-Onizuka T; Takimoto M; Nakamaki T; Ota H; Tomoyasu S
    Leukemia; 2007 Dec; 21(12):2563-6. PubMed ID: 17597802
    [No Abstract]   [Full Text] [Related]  

  • 43. Primary bone lymphoma: evaluation of chemoimmunotherapy as front-line treatment in 21 patients.
    Pellegrini C; Gandolfi L; Quirini F; Ruggieri P; Stefoni V; Derenzini E; Broccoli A; Argnani L; Pileri S; Mercuri M; Baccarani M; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):321-5. PubMed ID: 21816370
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Rituximab maintenance versus retreatment in follicular lymphoma.
    Palla AR; Hamadani M
    Hematol Oncol; 2013 Dec; 31(4):171-8. PubMed ID: 23044794
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Clinical Efficacy Comparison of Different Second Line Salvage Chemotherapy Regimens for the Treatment of Elderly Patients with Relapsed and Refractory Diffuse Large B Cell Lymphoma].
    Liu YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Apr; 24(2):448-51. PubMed ID: 27151008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
    Moore S; Peggs K; Thomson K; Lowry L; Ljubic A; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2012 Jan; 156(1):142-3. PubMed ID: 21848889
    [No Abstract]   [Full Text] [Related]  

  • 47. [A prospective multicenter study of rituximab combined with high-dose chemotherapy and autologous peripheral blood stem cell transplantation for aggressive B-cell lymphoma].
    Shi YK; Yang S; Han XH; Ma J; Ren HY; Cen XN; Zhou SY; Wang C; Jiang WQ; Huang HQ; Wang JM; Zhu J; Chen H; Han MZ; Huang H; Shen XM; Liu P; He XH
    Zhonghua Zhong Liu Za Zhi; 2009 Aug; 31(8):592-6. PubMed ID: 20021946
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
    [TBL] [Abstract][Full Text] [Related]  

  • 49. R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: influence of prior autologous stem-cell transplantation on outcome.
    Martín A; Caballero MD;
    Haematologica; 2009 May; 94(5):744. PubMed ID: 19336744
    [No Abstract]   [Full Text] [Related]  

  • 50. Clinical outcomes of a novel combination of lenalidomide and rituximab followed by stem cell transplantation for relapsed/refractory aggressive B-cell non-hodgkin lymphoma.
    Cai Q; Chen Y; Zou D; Zhang L; Badillo M; Zhou S; Lopez E; Jiang W; Huang H; Lin T; Romaguera J; Wang M
    Oncotarget; 2014 Sep; 5(17):7368-80. PubMed ID: 25228589
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Accelerated therapeutic progress in diffuse large B cell lymphoma.
    Cai Q; Westin J; Fu K; Desai M; Zhang L; Huang H; Jiang W; Liang R; Qian Z; Champlin RE; Wang M
    Ann Hematol; 2014 Apr; 93(4):541-56. PubMed ID: 24375125
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Simultaneous occurrence of large B-cell non-Hodgkin lymphoma and acute myeloid leukaemia in an elderly patient: complete remissions of both diseases by rituximab-bendamustine regimen combined to hypomethylating therapy.
    Palombi M; Niscola P; Tendas A; Trawinska MM; Scaramucci L; Giovannini M; Fratoni S; Perrotti A; de Fabritiis P
    J Chemother; 2013 Aug; 25(4):247-9. PubMed ID: 23906078
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab.
    Liu CY; Teng HW; Lirng JF; Chiou TJ; Chen PM; Hsiao LT
    Leuk Lymphoma; 2008 Oct; 49(10):2018-21. PubMed ID: 18728965
    [No Abstract]   [Full Text] [Related]  

  • 54. Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab.
    Tomuleasa C; Iluta S; Pasca S; Roman A; Piciu D; Jitaru C; Teodorescu P; Rus I; Bojan A; Dima D; Zdrenghea M; Petrushev B
    Int J Hematol; 2020 Oct; 112(4):597-598. PubMed ID: 32886277
    [No Abstract]   [Full Text] [Related]  

  • 55. [Thalidomide therapy in relapsed diffuse large B-cell lymphoma in elderly patients. Three cases].
    Wohner N; Varga G; Szloboda P; Farkas P; Masszi A; Horváth L; Szombath G; Várkonyi J; Benedek S; Masszi T
    Orv Hetil; 2017 Oct; 158(41):1642-1648. PubMed ID: 29025286
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settings.
    Rodrigues CA; Patah PA; Novis YA; Hosing C; de Lima M
    Curr Hematol Malig Rep; 2011 Mar; 6(1):47-57. PubMed ID: 21190142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diffuse large B-cell lymphoma: is there a place for autologous hematopoietic stem cell transplant in first remission in the era of chemo-immunotherapy?
    Nabhan C; Mehta J
    Leuk Lymphoma; 2012 Oct; 53(10):1859-66. PubMed ID: 22448919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.
    Cheah CY; Nastoupil LJ; Neelapu SS; Forbes SG; Oki Y; Fowler NH
    Blood; 2015 May; 125(21):3357-9. PubMed ID: 25999447
    [No Abstract]   [Full Text] [Related]  

  • 59. Immunomodulation therapy with lenalidomide in follicular, transformed and diffuse large B cell lymphoma: current data on safety and efficacy.
    Desai M; Newberry KJ; Romaguera J; Zhang L; Ou Z; Wang M
    J Hematol Oncol; 2013 Aug; 6():55. PubMed ID: 23915913
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.
    Marangon M; Stefoni V; Castellino A; Visco C; Tani M; Cox MC; Marasca R; Tecchio C; Devizzi L; Monaco F; Romano A; Rusconi C; Rigacci L; Castellino C; Gaudio F; Argnani L; Zinzani PL
    Clin Lymphoma Myeloma Leuk; 2019 Jul; 19(7):e321-e323. PubMed ID: 31080169
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.